Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912679 | 0.82 | IDO1 (0.41) | SLC6A2TAAR1SLC6A3IDO1ADRB1 | |
| SCHEMBL28071127 | 0.81 | SLC6A2 (0.62) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| SCHEMBL23458533 | 0.81 | TAAR1 (0.57) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| SCHEMBL31155410 | 0.80 | IDO1 (0.39) | SLC6A2TAAR1IDO1ADRB1CA12 | |
| SCHEMBL25343692 | 0.79 | SLC6A2 (0.42) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| SCHEMBL25343119 | 0.78 | ADRB1 (0.39) | SLC6A3IDO1ADRB1CA12CA1 | |
| SCHEMBL349725 | 0.78 | SLC6A2 (0.61) | SLC6A2TAAR1HTR2ASLC6A4HRH1 | |
| SCHEMBL564569 | 0.78 | ADRB1 (0.39) | SLC6A3IDO1ADRB1CA12CA1 | |
| SCHEMBL14456864 | 0.77 | ESR1 (0.41) | SLC6A2TAAR1IDO1ADRB1 | |
| Hydrochloric Acid SCHEMBL2799159 | 0.76 | SLC6A2 (0.59) | SLC6A2TAAR1HTR2ASLC6A4HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| EP-4225730-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076507-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-1562603-B3 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2014-01-08 | — | — | EP | disclosed |
| EP-1765355-B1 | BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8044046-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2011-10-25 | — | — | US | disclosed |
| US-7786111-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-31 | — | — | US | disclosed |
| US-7727984-B2 | R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino ]-ethyl}-4H-benzo[1,4]oxazin-3-one, or an acid addition salt thereof; betamimetics; for administration once a day for treating COPD | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-18 | — | — | US | disclosed |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
| WO-2005102350-A1 | BENZOXAZINE FOR TREATING RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1562603-A2 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | disclosed |
| WO-2004045618-A2 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256115-A1 | Aerosol formulation for the inhalation of beta-agonists | ADRB1, ADRB2, ADRB3 | SLC6A2 1271/4885TAAR1 197/4885HTR2A 1144/4885 |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | SLC26A4, CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A2 1663/4885TAAR1 1693/4885HTR2A 3703/4885 |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | MRGPRX2, MRGPRX1, CFTR | SLC6A2 3026/4885TAAR1 1634/4885HTR2A 2578/4885 |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | SLC6A2 1298/4885TAAR1 1628/4885HTR2A 3361/4885 |
| US-20050272726-A1 | Novel medicaments for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, CFTR | SLC6A2 3026/4885TAAR1 1634/4885HTR2A 2578/4885 |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | CLIC1, OTC, SLC10A1 | SLC6A2 2004/4885TAAR1 1403/4885HTR2A 3674/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | SLC6A2 713/4885TAAR1 1133/4885HTR2A 1568/4885 |
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | ADRB1, ADRB2, ADRB3 | SLC6A2 1271/4885TAAR1 197/4885HTR2A 1144/4885 |
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | SLC6A2 3591/4885TAAR1 4018/4885HTR2A 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.